ZFP36, ZFP36 ring finger protein, 7538

N. diseases: 161; N. variants: 3
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0178874
Disease: Tumor Progression
Tumor Progression
0.090 Biomarker phenotype BEFREE Electronic databases (up to June 7, 2018) were comprehensively searched to collect relevant cohort studies regarding the associations between NNMT expression levels and survival outcomes (overall survival [OS], disease-specific survival [DSS] including cancer-specific survival [CSS], and time to tumor progression [TTP] including disease-free survival [DFS], progression-free survival [PFS], and metastasis-free survival [MeFS]).Publication biases were also examined. 30349486 2018
CUI: C0178874
Disease: Tumor Progression
Tumor Progression
0.090 Biomarker phenotype BEFREE The prospective tumor suppressor tristetraprolin (TTP) has been shown to negatively regulate tumorigenesis through destabilizing the messenger RNAs of critical genes implicated in both tumor onset and tumor progression. 30380668 2018
CUI: C0178874
Disease: Tumor Progression
Tumor Progression
0.090 AlteredExpression phenotype BEFREE Taken together, our results suggest the overexpression of TTP in GC cells not only affects cell survival and apoptosis but also increases PBMLs -mediated cytotoxicity against GC cells to decelerate tumor progression. 29936792 2018
CUI: C0178874
Disease: Tumor Progression
Tumor Progression
0.090 Biomarker phenotype BEFREE We summarize TTP deficiency in several cancers and discuss that the lack of TTP can influence tumor progression at different aspects such as promoting cancer cell proliferation; accelerating cell cycle; improving survivability and resisting cell death; inducing angiogenesis; activating invasion and metastasis; inducing epithelial-mesenchymal transition; and deregulating cellular energetics. 29124478 2017
CUI: C0178874
Disease: Tumor Progression
Tumor Progression
0.090 PosttranslationalModification phenotype BEFREE We conclude that glioma cells suppress TTP function through phosphorylation of critical serine residues which in turn contributes to growth factor upregulation and tumor progression. 23525947 2013
CUI: C0178874
Disease: Tumor Progression
Tumor Progression
0.090 Biomarker phenotype BEFREE Median overall survival time (OS) and time to tumor progression after recurrence (TTP-2) were 17.5 and 7 months, respectively. 23898108 2013
CUI: C0178874
Disease: Tumor Progression
Tumor Progression
0.090 AlteredExpression phenotype BEFREE Finally, we survey potential mechanisms that cells may employ to suppress TTP expression in cancer, and propose potential diagnostic and therapeutic strategies that may exploit the relationship between TTP expression and tumor progression or senescence. 22387927 2012
CUI: C0178874
Disease: Tumor Progression
Tumor Progression
0.090 Biomarker phenotype BEFREE We reviewed 91 patients with HER2-positive MBC treated with trastuzumab and investigated correlations between survival and clinical response to first trastuzumab-based therapy and biological markers, time to first tumor progression (1st TTP), response rate (RR), estrogen receptor (ER), Ki-67, and p53 overexpression. 21556795 2011
CUI: C0178874
Disease: Tumor Progression
Tumor Progression
0.090 Biomarker phenotype BEFREE Tristetraprolin regulates interleukin-6, which is correlated with tumor progression in patients with head and neck squamous cell carcinoma. 21656745 2011